U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053345) titled 'A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression' on June 27.
Brief Summary: The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).
Study Start Date: June 09
Study Type: INTERVENTIONAL
Condition:
Depressive Disorder, Treatment-Resistant
Intervention:
DRUG: Esketamine 56 mg
Particip...